SOPHiA GENETICS Prices $50M Public Offering at $4.75/Share

summarizeSummary

SOPHiA GENETICS has priced its public offering of 10.5 million ordinary shares at $4.75 each, raising approximately $50 million for working capital and growth, an event met with a positive market response.

check_boxKey Events

• Public Offering Priced

  SOPHiA GENETICS has finalized the pricing of its underwritten public offering, selling 10,526,000 ordinary shares at $4.75 per share. This follows a preliminary prospectus supplement filed on June 16, 2026.

• Substantial Capital Raised

  The offering is expected to generate approximately $50.0 million in gross proceeds, or $46.0 million net of underwriting discounts and estimated offering expenses, providing significant capital for the company.

• Potential Dilution

  The issuance of 10,526,000 new shares represents a notable increase in outstanding shares, potentially diluting existing shareholders by approximately 14.7% based on shares outstanding as of March 31, 2026.

• Use of Proceeds

  The net proceeds are intended for working capital and general corporate purposes, including research and development, expanding sales and marketing efforts, establishing new collaborations, and obtaining regulatory approvals.

auto_awesomeAnalysis

This filing finalizes the terms and pricing of SOPHiA GENETICS' public offering, raising approximately $50 million through the sale of 10.5 million ordinary shares at $4.75 per share. While the offering is dilutive for existing shareholders, the successful securing of substantial capital for working capital, research and development, and strategic growth initiatives is a critical step for the company. The market's positive reaction, with shares advancing after the pricing announcement, indicates investor confidence in the company's ability to leverage these funds for future growth.